He lost 120 kg in 16 months, 55 kg in 18 months, 20 kg in xx months, and so on … at a time when she was “fit and fine”, a remarkable way to weight loss several television and film stars left a lot of thinking: they used some weight loss medicine?
Actor Ram Kapoor, producers of Boney Kapoor and Sajid Nadiadwala and Rapper Badshaah are the latest who joined the league. The reasons they claimed for their weight loss were more or less the same: a balanced diet, discipline, exercise and lifestyle changes.
However, their exceptional transformation led to speculation that they used blockbuster drugs, such as Novo Nordisk’s Ozemip or Wegovy. Not only these, but many other machines against machining entered the Indian market. Ozmpic was not officially launched in India.
Also read | Doctor responds to weight loss 26 kg Boney Kapoor without gymAlso read | The star of the great brother Kerry Riches shows stunning weight loss; Pictures here
A growing drug market for obesity
Drugs market for weight loss in India is experiencing rapid growth. According to the research company PharmarackAs the Economic Times quoted, the Indian drug market against obenite has seen significant growth £628 Crore since June 2025, a five -time increase in five years.
The Danish drug manufacturer Novo Nordisk and the opponent in the US Eli Lilly have seen an increase in demand for their obesity drugs Wegovy and Zepbound. It is estimated that the market will rise to $ 150 billion in the early 20th years.
How many drugs against obesity are available in India? How much does it cost? Are they really approved for weight loss? And do they help in weight loss? Here’s all you need to know:
List of medicines against machining available in the US
US food and drug administration (FDA) has been approved by six weight loss medicines for long -term use:
- Bupropion-naltrexon (Contrave)
- Liraglutide (saxenda)
- Orlistat (Xenical, Alli)
- Phentermine-toporamate (QSYMIA)
- Semaglutide (Wegovy)
- Setanotide (Imcivree)
- TIRZEPATID (ZEPBound)
There are many drugs that have not been licensed for the treatment of obesity.
Also read | Watch: RAM KAPOOR prevents the use of the height for weight loss
Which weight loss medicines are available in India?
Tirzepatide: According to a research article in the International Journal of Life Sciences, Biotechnology and Pharma Research was approved by the central drug standard in India recently in June 2024.
Oral semaglutide: According to MedantOral semaglutide is approved and available in India for use only in diabetes and obesity type 2.
Wegova: Another injection semaglutid Wegovy was approved for weight loss in case of obesity without type 2 diabetes and is available in India. WA was launched in India 24 June.
OZEM: Ozepic semaglutid is not “unchanged or (officially) available in India”.
Mounjaro: The Indian drug regulator approved the start of Eli Lilly for weight loss Mounjaro, Reuters informed June 26, 2025.
Also read | Drugs market for weight loss has become chaotic. What to know.
Grugs weight loss costs in India
1. Mounjaro and Zepbound
It is once a week injected with tirzepatide. The active component of Mounjaro, Tirzepatid, captured 8 percent of the market in India, Pharmarack said.
Is Mounjaro approved for weight loss? No, Mounjaro is not directly approved by the US FDA. Its active component, tripeptide, is approved for weight loss under the ZEPBound brand.
In India, however, Mounjaro Kwikpen was approved by the standard Central Drugs control organization for six dose strengths of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg, the company was cited by Reuters.
Costs in India: The drug is the price for £3 500 for 2.5 mg bottle and £4 375 for 5 mg bottle, Hindu informed. Mounjaro, usually taken once a week, would then stand between £14 000 and £17 500 per month, depending on the dose recommended by the doctor.
The average monthly price of Mounjaro in the US. is about $ 1,000 to $ 1,200 (approximately £86,000 to £1 lakh).
Also read | Novo Nordisk launches Wegovy drug weight loss for the price of £ 17 345 per monthAlso read | Weg’s weight loss remedy in India – how does it differ from Mounjaro?
2 .. Novo Nordisk’s Rybelsus
Rybelsus is used to treat diabetes. In India he was introduced in 2022 as an oral drug and is considered a breakthrough in the treatment of diabetes 2. Rybelsus contains the active substance Semaglutid.
Has Rybelsus Was he approved for weight loss? No. Was not approved for weight loss. However, the company claims that it can help lose weight. “While many people lost weight in medical studies, some gained weight,” the company’s website said.
Costs in India: Rybelsus is available as tablets (3, 7 and 14 mg) and can only be obtained with a prescription. Monthly costs come approximately to £10 000, reported business standard.
3. Novo Nordisk’s Wegova
The active ingredient of Wegovy is a semaglutide and dominates the market with two thirds of the share in India.
Is Weg’s approved for weight loss? Yes, Wegovy is approved by FDA for weight loss, but only if you are above a certain weight. This once weekly injection of weight loss exclusively for chronic weight control is available in five fixed pages: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg.
The FDA says Wegovy is approved to “reduce overweight and maintain a long -term weight reduction in some adults with obesity or overweight and some children with obesity, for use in addition to reduced calories and increased physical activity”.
COSTS: Weg’s cost in India ranges from £17 345 to £26 015 per month, depending on the dose.
-0.25 mg to 1 mg dose: £17 345/month
-1.75 mg dose: £24 280/month
-2.4 mg dose: £26 050/month
This translates roughly £4 366 for injection for the highest dose according to 1 mg.com.
Also read | Why New Agreements Wegovy will not resist the leadership of obesity Novo Nordisk
India get new and cheaper weight loss drugs?
Indian General Drug Manufacturers, including CIPLY, Dr. Reddy’s, Lupine and Cipla, raced to produce cheaper versions of Weg, when Semaglutid in 2026 from a patent.
The Semaglutide patent is expected to expire next year in several countries, including India in March. Semaglutid is an active ingredient of Wegbuster and Medicine Diabetes.
Novo Nordisk, which says it has been controlling about 70% of the global drug market, has lost exclusivity in many markets since 2026, with patents in India expire around April next year. This expiration of the patent does not include the US, Europe or Japan.
Several local and international drug manufacturers are looking at the Indian market. They are:
- Nordisk
- Eli lilly
- Sun Pharma
- Bonon
- Zydus lifesciences
- Cipp
- Dr. Reddy’s
- Lupine
- NATCO, human pharmacy, aurobindo pharma
Dr. Reddy’s, who aims to start the cheaper version of Copycat Weg in 87 countries next year, says his strategy is to focus on countries where Novo Nordisk does not hold patents on Semaglutid.
Dr. Initially, Reddy plans to launch a general version of Semaglutid in Canada, India, Brazil, Turkey and other developing markets, subject to the expiration of the patent, Israeli was quoted by Reuters.
Biopharmaceutical company BIOCON also plans to apply for approval of the Indian drug regulator by the end of 2026 and potentially launched in 2027 through a partner, CEO Siddharth Mittal told Reuters in -mail interview.
Are these drugs against obesity safe?
There are “prescription drugs” and “outside the designation” that were used in a way that differs from what the FDA approved.
“Off-Label” can be: “A drug approved for the treatment of another health problem; two or more drugs at the same time; National Institute of Diabetes and Digestive and Kidney Diseases.
It is said that weight management medicines are not for everyone with a high mass index (BMI). Obesity is defined as has a BMI 30 or higher.
It has been warned that while some machines against machining can be effective for weight loss, they can also carry potential risks and side effects and their long -term safety is still evaluated.
The research work published in September 2024 states that the effectiveness of tirzepatide (used in Mounjaro) in weight loss was better than other medicines. “But there were mild to middle gastrointestinal symptoms that were dependent on the dose and subsequently retreated,” he said.
“Rarely can become serious side effects. Therefore, it is important to ask your healthcare provider for all treatment options,” Mayo Clinic says.
“These drugs are not for everyone,” Mayo Clinic says. It recommends that one must not take prescription drugs, if you are trying to conceive, are pregnant or breastfeeding.
In addition, weight loss medicines may be expensive and insurance is not always paid.
The common side effects include:
1. Nausea, vomiting would be the most common side effects of semaglutide in clinical practice.
2. Free movements are rare, but are a common reason for not to tolerate the medicine.
3. Headache does not respond to conventional painkillers.
Obesity in India
According to a study published in the medical journal The Lancet, the occurrence of obesity and diabetes in India, which is one of the worst three globally for a high degree of obesity.
According to the National Family Health Survey (NFHS) -5 (2019-21), 24% of Indian women and 23% of Indian men with overweight or obese have 24% of Indian women and 23% of Indian men.
(Tagstotranslate) Obesity
